https://www.bloodpac.org/publications daily 0.75 2026-01-21 https://www.bloodpac.org/publications/generic-protocols-for-analytical-validation-of-tumor-informed-circulating-tumor-dna-assays-for-molecular-residual-disease-bloodpacs-mrd-analytical-validation-working-group-consensus-recommendation monthly 0.5 2026-01-21 https://www.bloodpac.org/publications/lexicon-for-clonal-hematopoiesis-in-liquid-biopsy monthly 0.5 2026-01-09 https://www.bloodpac.org/publications/analytical-validation-of-blood-derived-tumor-mutation-burden-btmb-assays-a-joint-consensus-recommendation-of-the-bloodpac-btmb-analytical-validation-working-group monthly 0.5 2025-10-06 https://www.bloodpac.org/publications/bloodpacs-collaborations-with-european-union-liquid-biopsy-initiatives monthly 0.5 2025-09-16 https://www.bloodpac.org/publications/minimum-technical-preanalytical-patient-and-clinical-context-data-elements-for-cerebrospinal-fluid-liquid-biopsy-recommendations-for-public-database-submissions monthly 0.5 2025-08-28 https://www.bloodpac.org/publications/recommended-clinical-context-and-patient-context-data-elements-for-liquid-biopsy-data-submitted-to-data-repositories-and-data-commons monthly 0.5 2025-04-23 https://www.bloodpac.org/publications/mnm5w9a9i1o4lybu7baizkxvz1tmz1 monthly 0.5 2025-04-23 https://www.bloodpac.org/publications/landscape-analysis-43b3f-mydmp monthly 0.5 2025-03-14 https://www.bloodpac.org/publications/landscape-analysis-43b3f monthly 0.5 2025-03-13 https://www.bloodpac.org/publications/landscape-analysis monthly 0.5 2024-08-23 https://www.bloodpac.org/publications/accessibility monthly 0.5 2024-08-23 https://www.bloodpac.org/publications/contrived-materials-and-a-data-set-for-the-evaluation-of-liquid-biopsy-tests monthly 0.5 2023-02-22 https://www.bloodpac.org/publications/bloodpac-collaborating-to-chart-a-path-towards-blood-based-screening-for-early-detection monthly 0.5 2023-02-20 https://www.bloodpac.org/publications/creating-standards-for-liquid-biopsies-the-bloodpac-experience monthly 0.5 2023-02-20 https://www.bloodpac.org/publications/the-blood-pac-data-commons-for-liquid-biopsy-data monthly 0.5 2023-02-20 https://www.bloodpac.org/publications/press-release-bloodpac-publishes-fda-reviewed-validation-protocols-for-liquid-biopsy monthly 0.5 2023-04-26 https://www.bloodpac.org/publications/three-types-of-covid-19-tests-needed-for-return-to-normalcy monthly 0.5 2023-02-20 https://www.bloodpac.org/publications/minimum-technical-data-elements-for-liquid-biopsy-data-submitted-to-public-databases monthly 0.5 2023-02-20 https://www.bloodpac.org/publications/getting-past-the-bad-blood-of-theranos-through-collaboration monthly 0.5 2021-02-15 https://www.bloodpac.org/publications/bloodpac-announces-milestone-in-accelerating-development-of-liquid-biopsy-for-cancer-initial-release-of-open-data monthly 0.5 2023-02-20 https://www.bloodpac.org/publications/category/News monthly 0.5 https://www.bloodpac.org/publications/category/Public+Comments monthly 0.5 https://www.bloodpac.org/publications/category/Podcast monthly 0.5 https://www.bloodpac.org/publications/category/Press+Release monthly 0.5 https://www.bloodpac.org/publications/category/Publication monthly 0.5 https://www.bloodpac.org/allevents daily 0.75 2026-03-20 https://www.bloodpac.org/allevents/16th-world-clinical-biomarkers-cdx-summit monthly 0.5 2026-03-20 https://www.bloodpac.org/allevents/bloodpacs-2026-q1-meeting monthly 0.5 2026-03-20 https://www.bloodpac.org/allevents/next-generation-diagnostics-summit monthly 0.5 2026-03-20 https://www.bloodpac.org/allevents/5th-liquid-biopsy-for-precision-oncology-summit-east-coast monthly 0.5 2026-03-20 https://www.bloodpac.org/allevents/iqn-path-annual-meeting monthly 0.5 2026-03-20 https://www.bloodpac.org/allevents/milken-institutes-virtual-roundtable monthly 0.5 2026-03-20 https://www.bloodpac.org/allevents/esmo-congress monthly 0.5 2026-01-21 https://www.bloodpac.org/allevents/aacr-annual-meeting monthly 0.5 2026-03-20 https://www.bloodpac.org/allevents/canaccord-genuity-early-cancer-detection-ecd-day monthly 0.5 2026-03-20 https://www.bloodpac.org/allevents/10th-liquid-biopsy-for-precision-oncology-2026 monthly 0.5 2026-01-12 https://www.bloodpac.org/allevents/bloodpac-2026-q1-meeting monthly 0.5 2026-01-07 https://www.bloodpac.org/allevents/improving-patient-access-to-liquid-biopsy-collection-regulatory-strategies-efficiencies monthly 0.5 2025-08-28 https://www.bloodpac.org/allevents/7th-annual-congress-of-liquid-biopsy monthly 0.5 2025-08-28 https://www.bloodpac.org/allevents/2025-prevent-cancer-dialogue monthly 0.5 2025-08-28 https://www.bloodpac.org/allevents/virtual-early-detection-screening-seminar monthly 0.5 2025-08-07 https://www.bloodpac.org/allevents/new-frontiers-virtual-seminar monthly 0.5 2025-09-16 https://www.bloodpac.org/allevents/webinar-cancer-patient-lab monthly 0.5 2025-06-17 https://www.bloodpac.org/allevents/amp-2025 monthly 0.5 2025-11-10 https://www.bloodpac.org/allevents/esmo-2025 monthly 0.5 2025-08-28 https://www.bloodpac.org/allevents/actc-2025 monthly 0.5 2025-09-17 https://www.bloodpac.org/allevents/webinar monthly 0.5 2025-08-13 https://www.bloodpac.org/allevents/4th-liquid-biopsy-for-precision-oncology-summit-east-coast monthly 0.5 2025-06-12 https://www.bloodpac.org/allevents/the-festival-of-genomics-biodata monthly 0.5 2025-06-02 https://www.bloodpac.org/allevents/bloodpac-2025-q3-meeting monthly 0.5 2025-07-02 https://www.bloodpac.org/allevents/american-association-for-cancer-research-aacr-annual-meeting monthly 0.5 2025-08-26 https://www.bloodpac.org/allevents/32nd-precision-medicine-tri-con monthly 0.5 2025-02-06 https://www.bloodpac.org/allevents/9th-liquid-biopsy-for-precision-oncology-summit monthly 0.5 2025-01-03 https://www.bloodpac.org/allevents/pmwc-2025 monthly 0.5 2025-01-07 https://www.bloodpac.org/allevents/x-liquid-biopsy-symposium monthly 0.5 2025-01-03 https://www.bloodpac.org/allevents/bloodpac-2025-q1-meeting monthly 0.5 2025-01-14 https://www.bloodpac.org/allevents/bloodpac-q3-2024-2g8s2-dpgws-jxpzy monthly 0.5 2025-08-21 https://www.bloodpac.org/allevents/bloodpac-q3-2024-2g8s2-dpgws-w2pmr monthly 0.5 2024-10-14 https://www.bloodpac.org/allevents/bloodpac-q3-2024-2g8s2-dpgws-ztrty monthly 0.5 2024-08-28 https://www.bloodpac.org/allevents/bloodpac-q3-2024-2g8s2-dpgws monthly 0.5 2024-08-28 https://www.bloodpac.org/allevents/bloodpac-q3-2024-2g8s2 monthly 0.5 2024-08-27 https://www.bloodpac.org/allevents/bloodpac-q3-2024 monthly 0.5 2024-08-22 https://www.bloodpac.org/allevents/rethinking-risk-and-risk-assessment-for-liquid-biopsy-based-single-and-multi-cancer-screening monthly 0.5 2024-03-05 https://www.bloodpac.org/allevents/bloodpac-q1-2024-meeting monthly 0.5 2024-05-10 https://www.bloodpac.org/allevents/panel-emerging-approaches-to-clinical-validation-of-mced-liquid-biopsy-tests monthly 0.5 2023-11-28 https://www.bloodpac.org/allevents/talk-creating-consensus-on-a-lexicon-for-cancer-early-detection-and-screening-liquid-biopsy-tests monthly 0.5 2023-11-28 https://www.bloodpac.org/allevents/talk-developing-standards-to-overcome-challenges-and-demonstrate-the-clinical-utility-of-liquid-biopsies-in-cancer-care monthly 0.5 2023-11-27 https://www.bloodpac.org/allevents/harnessing-liquid-biopsies-to-transform-cancer-treatment-selection-monitoring-early-detection-and-empower-precision-treatments monthly 0.5 2023-10-24 https://www.bloodpac.org/allevents/panel-discussion-creating-awareness-amongst-decision-makers-on-local-global-disparities-in-liquid-biopsy-research-and-practice-to-shape-an-inclusive-future-for-understudied-diseases monthly 0.5 2023-10-24 https://www.bloodpac.org/allevents/moving-towards-global-harmonization-of-liquid-biopsy-frameworks-and-standards-the-bloodpac-experience monthly 0.5 2023-10-13 https://www.bloodpac.org/allevents/panel-discussion-creating-consensus-on-lexicons-standards-frameworks-for-mced-and-mrd-tests-for-community-benefit monthly 0.5 2023-10-13 https://www.bloodpac.org/allevents/moving-towards-global-harmonization-of-liquid-biopsy-frameworks-and-standards-the-bloodpac-experience-talk monthly 0.5 2023-06-19 https://www.bloodpac.org/allevents/molecular-residual-disease-testing-confidence-and-consistency-in-mrd-assays monthly 0.5 2023-06-19 https://www.bloodpac.org/allevents/navigating-a-path-to-advance-the-use-of-liquid-biopsies-for-early-cancer-screening-and-detection-panel-discussion monthly 0.5 2023-05-31 https://www.bloodpac.org/allevents/creating-consensus-on-a-lexicon-standards-and-frameworks-for-multi-cancer-detection-talk monthly 0.5 2023-08-14 https://www.bloodpac.org/allevents/8imcm8tim4a97cpmvf1r4hzlzvgbbq monthly 0.5 2023-08-14 https://www.bloodpac.org/allevents/panel-discussion-on-ctdna-for-solid-tumor-drug-development monthly 0.5 2023-05-31 https://www.bloodpac.org/allevents/bloodpac-q1-meeting-2023 monthly 0.5 2023-06-19 https://www.bloodpac.org/allevents/strategic-collaboration-reaching-molecular-residual-disease-as-an-early-endpoint-for-solid-tumors-panel-discussion monthly 0.5 2023-05-31 https://www.bloodpac.org/allevents/standarizing-frameworks-and-democratizing-access-to-liquid-biopsy-talk monthly 0.5 2023-05-31 https://www.bloodpac.org/allevents/non-small-cell-lung-cancer-drug-development-summit-zfm63 monthly 0.5 2022-09-22 https://www.bloodpac.org/allevents/non-small-cell-lung-cancer-drug-development-summit monthly 0.5 2022-08-27 https://www.bloodpac.org/allevents/focused-ultrasound-and-liquid-biopsy-2022-symposium monthly 0.5 2023-05-24 https://www.bloodpac.org/allevents/pact-io-coordination-forum monthly 0.5 2022-08-01 https://www.bloodpac.org/allevents/gastrointestinal-drug-development-summit monthly 0.5 2022-08-01 https://www.bloodpac.org/allevents/festival-of-genomics-biodata-2022 monthly 0.5 2022-08-01 https://www.bloodpac.org/allevents/6th-annual-liquid-biopsy-for-precision-oncology-summit monthly 0.5 2022-08-01 https://www.bloodpac.org/allevents/bloodpac-summit-2022 monthly 0.5 2022-08-01 https://www.bloodpac.org/allevents/new-frontiers-personalized-medicine-for-brain-cancer-in-adults-and-children monthly 0.5 2022-08-24 https://www.bloodpac.org/bloodpac-blog daily 0.75 2025-11-17 https://www.bloodpac.org/bloodpac-blog/performancemetrics-in-earlydetection monthly 0.5 2025-11-17 https://www.bloodpac.org/bloodpac-blog/statnews-accessibility-op-ed monthly 0.5 2025-11-17 https://www.bloodpac.org/bloodpac-blog/newsletter-q1-q2-2024 monthly 0.5 2024-08-23 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/56f4036b-fe09-49ee-bd76-c8e55fda556a/IMG_8450.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1-Q2 2024 - Q1 In-person Meeting Our invite-only Q1 meeting was generously hosted by Illumina in San Diego, CA. Attendees met in working group sessions on day 1 and presented updates, accomplishments, and next steps on day 2 in our all-members meeting. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/548a95d1-17be-4665-bdcc-89606ba6636a/IMG_4029.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1-Q2 2024 - Early Detection AACR Session On April 6, 2024, at the AACR Annual Meeting, BLOODPAC hosted a special session on "Rethinking Risk and Risk Assessment for Liquid Biopsy-Based Single- and Multi-Cancer Screening." Panelists from Natera, GRAIL, the NCI, Guardant, Friends of Cancer Research, and Dana Farber discussed how the field is currently conceptualizing cancer risk in the setting of cancer screening guidelines, and whether we need to shift our thinking and terminology with the introduction of new single and multi-cancer early detection technologies. You can read the abstract here and a recap of the session here. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/75995e97-f47d-43b5-ac7c-a4fbf90ab9d3/Cover.png BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1-Q2 2024 - CHIP White Paper If you missed our New Frontiers seminar on clonal hematopoiesis of indeterminate potential (CHIP) in December, a recording of the event and a white paper are available here! The seminar featured leading experts presenting their work on CHIP, covering topics from novel classification methods to CHIP as a risk factor for cardiovascular disease and heme malignancies. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/0cd45038-2d77-4134-8fd7-796c0b969556/Copy+of+New+Social+Media+Templates+%28Instagram+Post%29.png BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1-Q2 2024 - BLOODPAC welcomes new members! Tasso is a Seattle-based startup developing at-home blood collection kits for both liquid blood and dried blood spots. The International Society of Liquid Biopsy (ISLB) founded in 2017 in Granada, Spain, ISLB brings together healthcare professionals, primarily oncologists, who have adopted liquid biopsies as a new clinical tool. Tecan a Swiss company that supports customers in healthcare and life sciences from early-stage innovation to project implementation and beyond. https://www.bloodpac.org/bloodpac-blog/bloodpac-aacr24-rethinking-risk monthly 0.5 2024-06-17 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/75108380-4cc2-49ea-820d-5f40afe24ebe/IMG_4029.jpg BLOODPAC Blog - Rethinking risk and risk assessment for liquid biopsy-based single- &amp; multi-cancer screening - Make it stand out AACR24 Rethinking Cancer Risk and Risk Assessment for Liquid Biopsy-Based Single- and Multi-Cancer Screening session. Speakers from left to right: Lauren Leiman, MBA (Executive Director, BLOODPAC), Bree Mitchell, PhD (Senior Director, Translational Medicine and Research, Natera), Christina Clarke Dur, PhD MPH (VP Epidemiology, Distinguished Scientist, GRAIL), Wendy Rubinstein, PhD (Senior Scientific Officer, Division of Cancer Prevention, National Cancer Institute), Elizabeth (Betsy) O’Donnell, MD, DipABLM (Director of Early Detection and Prevention of Malignant Conditions, Dana-Farber Cancer Institute), Jeff Allen, PhD (President and CEO, Friends of Cancer Research), and Victoria Raymond, MS (Sr. Director, Medical Affairs, Guardant Health) https://www.bloodpac.org/bloodpac-blog/jco-lb-equitable-implementation-podcast monthly 0.5 2024-06-17 https://www.bloodpac.org/bloodpac-blog/newsletter-q3-2023 monthly 0.5 2024-02-29 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/66fdce1f-af92-4e28-9d4f-6ae69f9b4349/IMG_2254.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q3 2023 - Our invite-only Q3 meeting was generously hosted by Streck in Omaha, Nebraska. Our members spent the first day in working group sessions, followed by a day of day of updates, discussions and anticipated paths forward from each group. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/072729f2-56b2-4bda-8bb6-a89e720085e4/Copy+of+New+co-chair+announcement+Jon++%281%29.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q3 2023 - BLOODPAC is thrilled to welcome Elizabeth Mansfield (VP, Regulatory Policy, Foundation Medicine) to our Scientific Co-Chair Committee! Liz has over 20 years of experience in regulatory affairs, including a decade of service at the FDA. Liz is a longtime member of our Analytical Validation working groups, and we are so excited she is joining BLOODPAC's leadership! https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2475097c-258d-4cd1-8350-8757a162d0d8/Genece+New+Member+%281%29.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q3 2023 - BLOODPAC welcomes Genece, our newest member! Genece Health is committed to advancing the field of oncology with the goal of providing an accessible tool to identify cancer earlier in its progression. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/909fdf70-a707-4b1e-9269-667efe187e70/IMG_20230822_102134.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q3 2023 - Last month, BLOODPAC hosted a panel discussion at the Next Generation Dx 2023 Summit on our work in developing and executing a strategic plan for MRD implementation. Thank you panelists Gregory Jones (Head of Precision Diagnostics, NeoGenomics) and Christina Lockwood (Associate Professor, University of Washington)! https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2341505a-29e5-44d5-a0ea-7fd90ce7ac64/AV+Protocols+blog+post.png BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q3 2023 - This past spring, we initiated a call for feedback on our published AV protocols for ctDNA assays in order to ensure these documents continue to be up-to-date and useful. We were thrilled to receive insightful responses from a broad range of protocol users, and are working on incorporating this feedback into a revised version for publication in the new year. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/ce013e0c-203d-42cd-a981-bf221feedff9/Leiman.png BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q3 2023 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/bloodpac-blog/circulating-tumor-cells monthly 0.5 2024-05-10 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/143e5001-d83b-401a-8443-05870dd2b0f3/Contrived+materials+%282%29.jpg BLOODPAC Blog - Understanding Circulating Tumor Cell-Based Liquid Biopsy - Make it stand out Liquid biopsy can be used to isolate circulating tumor cells from the bloodstream. Figure created with Biorender. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/94003d28-a0f6-4ab0-af8d-51fd582755fc/CTCs_isolation.jpg BLOODPAC Blog - Understanding Circulating Tumor Cell-Based Liquid Biopsy - Make it stand out Circulating tumor cell isolation techniques. Figure adapted from Ju et al. (Biomarker Research) 2022. https://www.bloodpac.org/bloodpac-blog/early-cancer-detection monthly 0.5 2023-07-07 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/0d7408c1-be77-4c71-86bd-999f54df842c/MCD_test_image.png BLOODPAC Blog - Understanding Liquid Biopsy for Early Cancer Detection and Screening - Make it stand out An overview of several multi-cancer detection assays in development and commercially available. Figure from Liu (2021), British Journal of Cancer. https://www.bloodpac.org/bloodpac-blog/newsletter-q2-2023 monthly 0.5 2024-01-28 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/c528cd0f-6472-4bdd-95ff-2a600906d416/-605139969515612418.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q2 2023 - At our invite-only Q2 meeting at ASCO, several working groups presented on their progress to date. Thank you to all attendees for a productive and thoughtful discussion, allowing us to align on next steps and continue meeting our promise to cancer patients and the liquid biopsy community. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/4827e29e-2f89-4f64-ac28-2be86951b12f/Copy+of+AV+Protocols+blog+post.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q2 2023 - We're excited to welcome Jon Baden (Head of Solid Tumor Oncology Diagnostics, BMS) and Angela Silvestro (Director, Companion Diagnostics, GSK) to BLOODPAC's Scientific Co-Chair Committee! https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2341505a-29e5-44d5-a0ea-7fd90ce7ac64/AV+Protocols+blog+post.png BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q2 2023 - BLOODPAC initiated an open comment period on our generic protocols for the analytical validation of ctDNA assays. Our goal is to learn how the community uses these protocols and whether any updates are warranted. If you've read or used the protocols, we'd love to hear from you by July 24th! You can find the full text of the protocols and the feedback form here. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/dea54507-9386-4b24-a005-1b1ec4a7f14d/AACR_panel_2023.jpeg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q2 2023 - At AACR, BLOODPAC member Jon Baden (BMS) represented the consortium on a panel discussion with the FDA entitled "Liquid Biopsies for Curative-Intent Solid Tumor Drug Development." We had a great turnout, with over 250 attendees! https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/617b2c12-7405-4868-b2ce-2322c598ad94/1067200_SocialMedia-Webinar-1200%C3%97675.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q2 2023 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/bloodpac-blog/understanding-bloodpacs-analytical-validation-protocols-for-ctdna-assays monthly 0.5 2023-05-01 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/75acc00f-3fa0-43a0-83f1-a3128dd531e0/validation_process_figure.png BLOODPAC Blog - Understanding BLOODPAC’s Analytical Validation Protocols for Late-Stage Solid Tumor ctDNA Assays - Make it stand out Analytical validation is a critical part of the assay development process. While pre-analytical validation covers sample acquisition, processing, and storage, analytical validation ensures that the assay accurately and reliably works as intended. Figure from Masucci et al. (2016). https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/588a720d-f9e0-441e-aebc-636c1e006067/AVprotocols_figure.jpg BLOODPAC Blog - Understanding BLOODPAC’s Analytical Validation Protocols for Late-Stage Solid Tumor ctDNA Assays - Make it stand out Protocols and methods included in BLOODPAC’s Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays. The complete documents are available in the supplementary material of the publication. https://www.bloodpac.org/bloodpac-blog/liquid-biopsy-brain-cancer monthly 0.5 2023-04-20 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2e1a64a2-928b-456c-a067-6acd6409d133/CSF_brain_cancer_image.png BLOODPAC Blog - Understanding Liquid Biopsy for Brain Cancer - Make it stand out Liquid biopsy is an exciting potential addition of the standard-of-care (SOC) for brain cancer patients, providing a host of new information about the molecular characteristics of the tumor and putative biomarkers to track response to therapy. Figure from Escuerdo et al. (2021), found here. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/30531c09-0e47-480b-b713-470305459e9a/nci-vol-4279-72.gif BLOODPAC Blog - Understanding Liquid Biopsy for Brain Cancer - Make it stand out Cerebrospinal fluid (CSF) is found within the ventricles, around the brain and spinal cord, and between the meninges. Image from National Cancer Institute. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1327d009-42c4-4481-b284-f13bc522fdb0/LBx+for+brain+cancer+patient+journey.jpg BLOODPAC Blog - Understanding Liquid Biopsy for Brain Cancer - Make it stand out Liquid biopsy in brain cancer has multiple use cases along the patient journey. The field is still working to understand the most complementary uses of this technology in the context of the current standard-of-care, as shown above. Figure created with Biorender. https://www.bloodpac.org/bloodpac-blog/newsletter-q1-2023 monthly 0.5 2024-01-28 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/9c147889-6788-4b54-81fb-a5dc9c075fd7/Twitter++Q1+Meeting.png BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1 2023 - We just finished hosting our in-person Q1 meeting in Washington, DC! A big thank-you to our working group co-chairs and speakers, our colleagues on the PROMETHEUS project, and all attendees for a productive and creative meeting. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/a2abefeb-a98f-40d1-bbd0-f5ab2096f868/JFDI-Diagram.png BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1 2023 - Congrats to the JFDI working group, who just published the result of their study on the use of contrived materials for comparative evaluation of liquid biopsy assays! Read the full article here https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/034c5a1d-5c0a-42d8-b285-b413064baf44/Copy+of+LinkedIn++New+Pub+10172022+alt.png BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1 2023 - Our Early Detection and Screening working group authored a paper on the opportunities and challenges of liquid biopsy for early cancer detection! Read the full article here https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2e1147b8-80ba-4311-aee1-5e0fe30f78f3/IMG_0022.jpg BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1 2023 - BLOODPAC hosted a panel discussion at TriCon 2023 in San Diego last month—thank you to our panelists Duane Hassane (Tempus), Minetta Liu (Natera), Asaf Zviran (C2i Genomics) and Angela Silvestro (GSK)! https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/a38269a3-1b81-49ac-861a-db3ed7fdf77f/AACR23+RegSci+-+Liquid+Bx+panel+Ad.PNG BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1 2023 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/30a09f0e-54c3-4fa8-bc2c-8ca11e5d6cd3/NCI_workshop.png BLOODPAC Blog - BLOODPAC Quarterly Newsletter: Q1 2023 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/bloodpac-blog/mrd-clinical-trials monthly 0.5 2023-06-01 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2db0492b-c140-464b-a8fb-d7840693feac/MRD+across+patient+journey+%281%29.jpg BLOODPAC Blog - Understanding Molecular Residual Disease (MRD) in Clinical Trials - Make it stand out MRD testing can be used throughout the patient journey to provide actionable information. Following initial treatment, MRD testing could be used to monitor for recurrence and determine if a patient could benefit from additional therapy to lower the risk of relapse. During the course of treatment, ctDNA can be used the monitor patient response over time and inform decisions on whether to continue or change therapy. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/e269d6aa-94f8-4480-ab1a-d5cb2946064b/blog+post+image.jpg BLOODPAC Blog - Understanding Molecular Residual Disease (MRD) in Clinical Trials - Make it stand out An example of ctDNA monitoring incorporated into clinical trial design: the ongoing CIRCULATE-Japan study, composed of three parallel clinical trials, evaluates the clinical benefits of ctDNA analysis and precision adjuvant therapy for resectable colorectal cancer. Abbreviations: F/U, follow up; FTD/TPI, trifluridine/tipiracil; mo, month; NAC, neoadjuvant chemotherapy; Op, operative; WES, whole-exome sequencing. Figure from Taniguchi et al. Cancer Science (2021). https://www.bloodpac.org/bloodpac-blog/thought-leaders-in-liquid-biopsy-dr-howard-scher monthly 0.5 2023-03-21 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/e54ecd97-df66-4cd6-8503-f6e69341ba35/howard_scher.jpg BLOODPAC Blog - Thought Leaders in Liquid Biopsy: Dr. Howard Scher (Memorial Sloan Kettering Cancer Center) - Dr. Howard Scher is an attending physician and Head of Biomarker Development at Memorial Sloan Kettering (MSK) Cancer Center and Professor of Medicine at the Weill Cornell Medical College. His research focuses on cellular signaling mechanisms in prostate cancer, and Dr. Scher has been involved in clinical trials for novel cancer therapeutics for many years. https://www.bloodpac.org/bloodpac-blog/mrd-solid-tumors monthly 0.5 2023-06-21 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/74b6be4f-0d5a-476a-abcd-e55658f293df/Liquid+Biopsy+General+%281%29.jpg BLOODPAC Blog - Understanding Molecular Residual Disease (MRD) in Solid Tumors - Make it stand out In general, a liquid biopsy involves taking a blood draw from a patient and analyzing the circulating cell-free DNA for the presence of cancer, such as tumor-derived DNA containing mutations or epigenetic modifications. Image created with BioRender.com https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1eaf8ae2-8065-4bca-adac-13f4e3235f2d/MRD_image.jpg BLOODPAC Blog - Understanding Molecular Residual Disease (MRD) in Solid Tumors - Make it stand out MRD testing can be used throughout the patient journey to provide actionable information. After initial treatment, MRD testing could be used to determine if a patient could benefit from additional therapy to lower the risk of relapse. During the course of treatment, ctDNA can be used the monitor patient response over time and inform decisions on whether to continue or change therapy. Finally, MRD testing can be used to monitor for recurrence after a patient has tested negative and is presumed to have no evidence of disease. Image from Moding & Diehn, Nature Cancer (2020). https://www.bloodpac.org/bloodpac-blog/thought-leaders-anne-marie-martin monthly 0.5 2023-03-10 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2fbdd5ae-7dad-4e91-ac4b-872450fc4342/Anne-Marie+Martin+headshots.jpg BLOODPAC Blog - Thought Leaders in Liquid Biopsy: A Conversation with Dr. Anne-Marie Martin (Global Head of Experimental Medicine, GSK) - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/bloodpac-blog/understanding-tmb monthly 0.5 2023-03-10 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b6e3e8c4-ec6e-4e3b-b4e6-1096142901ec/cancer-cell-transformation+%281%29.png BLOODPAC Blog - Understanding Tumor Mutational Burden (TMB) - Make it stand out Normal cells become cancerous through the acquisition of mutations and subsequent uncontrolled division. Image created with Biorender.com https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/25810409-41a8-4d1a-a9f3-7108ab45a571/survival_graph.jpg BLOODPAC Blog - Understanding Tumor Mutational Burden (TMB) - Make it stand out Kaplan-Meier overall survival curves for Stage IV renal cell carcinoma patients, stratified by immunotherapy treatment (+/- ICI) and tumor mutational burden (Low/High TMB). Patients with high TMB had higher overall survival when treated with immunotherapy than low-TMB patients. Data from Wood et al. Genome Med, https://doi.org/10.1186/s13073-020-00729-2 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/c4d9676b-6818-4e62-83a5-80e2e8e58939/Liquid+Biopsy+General+%281%29.jpg BLOODPAC Blog - Understanding Tumor Mutational Burden (TMB) - Make it stand out In general, a liquid biopsy involves taking a blood draw from a patient and analyzing the circulating cell-free DNA for the presence of cancer, such as tumor-derived DNA containing mutations or epigenetic modifications. Image created with BioRender.com https://www.bloodpac.org/bloodpac-blog/thought-leaders-phil-febbo-illumina monthly 0.5 2023-03-10 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/9e7889eb-ae2a-4266-baaa-2d2870ea867d/Phil+Febbo+Headshot.jpg BLOODPAC Blog - Thought Leaders in Liquid Biopsy: A Conversation with Dr. Phil Febbo (CMO, Illumina) Phil Febbo, MD is the Chief Medical Officer at Illumina. Prior to joining the company, Dr. Febbo ran a translational laboratory focused on using genomics to understand prostate cancer at the University of California-San Francisco and practiced as a genitourinary oncologist. Throughout his career, Dr. Febbo has served as a primary investigator for the Translational Research Program of The Alliance for Clinical Trials in Oncology, where his work focused on incorporating biomarkers into large clinical trials. At Illumina, Dr. Febbo is responsible for developing and executing the company’s medical strategy to drive genomic testing into healthcare practice. https://www.bloodpac.org/bloodpac-blog/contrived-materials-explainer monthly 0.5 2023-03-10 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3614f1ca-9aca-4ab4-87b8-90df5fa97339/Contrived+materials+%281%29.jpg BLOODPAC Blog - Contrived Materials in Liquid Biopsy Assay Development - Make it stand out Contrived materials are generally manufactured using human cell line DNA, with the desired variant alleles incorporated in known amounts. Image created using Biorender.com https://www.bloodpac.org/bloodpac-blog/contrived-materials-paper-bloodpac monthly 0.5 2024-08-22 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/7c4864fd-6c27-4abf-99e3-f80e7bce6a0d/LinkedIn++JFDI+02.png BLOODPAC Blog - New Paper on Contrived Materials in Liquid Biopsy Validation from BLOODPAC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/bloodpac-blog/early-cancer-screening monthly 0.5 2023-03-09 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/314eb23e-a861-4a89-a04c-67d136fcd45b/LinkedIn_New+Pub_101722alt.png BLOODPAC Blog - BLOODPAC Publishes a Roadmap for Early Cancer Detection and Screening using Liquid Biopsy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/bloodpac-blog/s/fusf-liquid-biopsy-report-3-web-pages-lorespdf monthly 0.5 2023-03-09 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/fbc456eb-f9e5-4005-8633-f67b74f8e8c1/Liquid-Biopsy-Virtual-Workshop-2022-cover-500x648.png BLOODPAC Blog - BLOODPAC Hosts Brain Cancer Virtual Webinar On March 30, 2022, BLOODPAC partnered with the Focused Ultrasound Foundation and C2i Genomics to host the virtual workshop, “New Frontiers in Liquid Biopsy: Personalized Medicine for Brain Cancer in Adults and Children.” The content of the webinar, a BLOODPAC members-only event, is now available to the general public. The Focused Ultrasound Foundation has published a White Paper on the webinar and is available here. BLOODPAC and the Focused Ultrasound Foundation established a partnership in 2020 to explore focused ultrasound’s potential to enhance this burgeoning field. It has been suggested that the yield of liquid biopsies in brain cancers is limited by the BBB, which prevents brain tumor markers from entering the bloodstream. Several preclinical studies have indicated that focused ultrasound can be used to open the BBB and amplify the presence of biomarkers in patients with glioblastomas, making them easier to detect and measure in the bloodstream. A first-in-human clinical trial published in Neuro-Oncology suggested that focused ultrasound could reduce the need for invasive brain tumor biopsies and allow better monitoring of brain tumor treatment responses. Having the ability to monitor genetic and epigenetic changes with a simple blood test could also allow for improved precision medicine and guide targeted therapies along the course of a patient’s treatment. The recent workshop addressed the potential use of liquid biopsies for patients with brain tumors. Nir Lipsman, MD, PhD, a pioneer in focused ultrasound applications for the brain, gave a lecture on the potential use of focused ultrasound–enhanced liquid biopsies for brain tumors. Another speaker, Manmeet Ahluwalia, MD, will lead an upcoming clinical trial assessing the efficacy of liquid biopsy for recurrence monitoring of patients with primary brain cancer. The session also featured presentations by Stephen Bagley, MD, who previously presented a Foundation webinar on liquid biopsy, and Matija Snuderi, MD. Panelists Kirk Tanner, PhD, from the National Brain Tumor Society; Patrick Wen, MD, from the Dana Farber Cancer Institute; Lauren Abrey, MD, from Novartis; and Uri Weinberg, MD, PhD, from Novocure discussed key barriers, identified challenges, and began creating a roadmap to move the field forward. “We are encouraged that the members of BLOODPAC want to learn more about brain tumors and how liquid biopsy could aid in the diagnosis, guide precision medicine, and provide follow-up for patients with brain tumors, especially children,” said the Foundation’s Director of Clinical Relationships, Suzanne LeBlang, MD. “Lauren Leiman, the Director of BloodPAC, provided a truly unique opportunity to convene the community and help improve the care of patients with such aggressive brain tumors as GBM and DIPG.” https://www.bloodpac.org/bloodpac-blog/podcast-building-collaboration monthly 0.5 2023-03-09 https://www.bloodpac.org/bloodpac-blog/covid-19-testing-framework monthly 0.5 2023-03-09 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/e14c19f0-2763-4286-96a9-380e66037ac6/covid_paper.png BLOODPAC Blog - BLOODPAC Working Group Publishes on COVID-19 Testing Requirements - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/bloodpac-blog/statement-of-support-from-cap monthly 0.5 2023-03-09 https://www.bloodpac.org/bloodpac-blog/bloodpac-moves-forward-with-liquid-biopsy-data-commons monthly 0.5 2023-03-09 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/ef951604-1b15-43f3-9406-2a78119e5e53/DC+LifeCycle+_+LinkedIn.png BLOODPAC Blog - BloodPAC Moves Forward With Liquid Biopsy Data Commons</a> - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/bloodpac-blog/bcrf-and-pcf monthly 0.5 2023-03-09 https://www.bloodpac.org/bloodpac-blog/bloodpac-announces-milestone-in-accelerating-development-of-liquid-biopsy-for-cancer-initial-release-of-open-data-p8bl3-hp865 monthly 0.5 2023-03-09 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/e2523a5a-619f-4c31-8fef-4b8e15a13815/moonshot_image.jpg BLOODPAC Blog - Blood Profiling Atlas in Cancer: Identifying the Mission - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/bloodpac-blog/bloodpac-announces-milestone-in-accelerating-development-of-liquid-biopsy-for-cancer-initial-release-of-open-data-p8bl3-hp865-theht monthly 0.5 2023-03-09 https://www.bloodpac.org/bloodpac-blog/category/Events monthly 0.5 https://www.bloodpac.org/bloodpac-blog/category/News monthly 0.5 https://www.bloodpac.org/bloodpac-blog/category/Liquid+Biopsy+Technology monthly 0.5 https://www.bloodpac.org/bloodpac-blog/category/Member+Spotlight monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/cancer+screening monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/blood-based+cancer+test monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/recurrence+monitoring monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/data monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/frameworks monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/accessibility monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/thought+leaders monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/COVID-19 monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/Newsletter monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/brain+tumors monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/CSF monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/podcast monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/immunotherapy monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/contrived+materials monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/early+cancer+screening monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/liquid+biopsy monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/events monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/CTCs monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/clinical+trial monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/Data+Commons monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/treatment+decision monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/breast+cancer monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/BCRF monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/bTMB monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/brain+cancer monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/surrogate+endpoint monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/assay+development monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/MTDEs monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/standards monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/PCF monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/prostate+cancer monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/molecular+residual+disease monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/cancer+early+detection monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/liquid monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/Cancer+Moonshot monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/analytical+validation monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/collaboration monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/BLOODPAC monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/reference+materials monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/Policy+and+Reimbursement monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/minimal+residual+disease monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/early+endpoint monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/explainer monthly 0.5 https://www.bloodpac.org/bloodpac-blog/tag/MRD monthly 0.5 https://www.bloodpac.org/public-comments-2 daily 0.75 2023-12-27 https://www.bloodpac.org/public-comments-2/reasonableandnecessary monthly 0.5 2023-02-20 https://www.bloodpac.org/public-comments-2/dl38290 monthly 0.5 2023-02-20 https://www.bloodpac.org/public-comments-2/dl38043 monthly 0.5 2023-02-20 https://www.bloodpac.org/public-comments-2/cms1678p monthly 0.5 2023-02-20 https://www.bloodpac.org/lexicon daily 0.75 2025-03-13 https://www.bloodpac.org/lexicon/vocabulary1-xty8j-pdr5y monthly 0.5 2025-03-13 https://www.bloodpac.org/lexicon/vocabulary1-xty8j monthly 0.5 2025-03-13 https://www.bloodpac.org/lexicon/vocabulary1 monthly 0.5 2025-03-13 https://www.bloodpac.org/lexicon/category/CHIP monthly 0.5 https://www.bloodpac.org/lexicon/category/Early+Detection+%26+Screening monthly 0.5 https://www.bloodpac.org/lexicon/category/MRD monthly 0.5 https://www.bloodpac.org/portal-publications daily 0.75 2025-12-09 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1608066266418-CHQC49XZZNQKNA7TGGP4/20140228_Trade-151_0046.jpg Refresh - BLOODPAC Portal https://www.bloodpac.org/portal-publications/blog-post-title-one-x5l29 monthly 0.5 2025-11-25 https://www.bloodpac.org/portal-publications/blog-post-title-two-eglaz monthly 0.5 2020-05-19 https://www.bloodpac.org/portal-publications/blog-post-title-three-hmgks monthly 0.5 2020-05-19 https://www.bloodpac.org/portal-publications/blog-post-title-four-hz2l2 monthly 0.5 2020-05-19 https://www.bloodpac.org/portal-publications/tag/Cellular+Data monthly 0.5 https://www.bloodpac.org/portal-publications/tag/Clinical monthly 0.5 https://www.bloodpac.org/portal-publications/tag/FASTQ monthly 0.5 https://www.bloodpac.org/portal-publications/tag/Breast+Cancer monthly 0.5 https://www.bloodpac.org/portal-publications/tag/Blood monthly 0.5 https://www.bloodpac.org/portal-publications/tag/BAM monthly 0.5 https://www.bloodpac.org/portal-publications/tag/CTC monthly 0.5 https://www.bloodpac.org/portal-publications/tag/cfDNA monthly 0.5 https://www.bloodpac.org/portal-publications/tag/Cellular+Analysis monthly 0.5 https://www.bloodpac.org/portal-publications/tag/Rare+Cell+Detection%2FEnumeration monthly 0.5 https://www.bloodpac.org/portal-publications/tag/Stage+IV monthly 0.5 https://www.bloodpac.org/portal-publications/tag/NGS monthly 0.5 https://www.bloodpac.org/portal-publications/tag/Detection monthly 0.5 https://www.bloodpac.org/portal-publications/tag/Annotated+Excel monthly 0.5 https://www.bloodpac.org/story daily 0.75 2026-03-09 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/330449ea-d008-4b70-9054-de51298463d5/IMG_2955.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/aee04673-cab8-4d59-ab1e-692aced0dfd3/phil.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d48c345f-25ad-458c-a712-76b4195b8c1d/evidence.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b0680bd2-ce34-467c-8940-5e05153dbf9a/data.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/15ba8d59-b26a-4ba4-a7d9-cbd4d8dba2b5/stakeholder.png https://www.bloodpac.org/contact-us daily 0.75 2024-12-10 https://www.bloodpac.org/team daily 0.75 2025-11-14 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/7466705f-564b-4eb2-bea4-95160cb9ed2a/Lauren+Leiman+Headshot.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b8e5c139-b1cd-4a9e-9a56-693a16a6f1e5/HS-PHILLIP+G.+FEBBO%2C+MD.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1611718968756-CWXXP6BXXACRRJ7TC1ZM/HS-RobGrossman.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1613406013585-OAGWYSAPUAVVF3ECTDAD/Peter.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/eae6322f-4147-4276-a441-7266168f8894/Nancy+Krunic-2024.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1611719016392-MW1FVVM6J93MN7GJ1G0B/HS-JakeVinson.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/605d23f3-5301-4ab3-ae8a-21ab76f91876/Jon_baden_headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1613241600206-A3IHBJ7B3L8KNIZ1JVYG/Kelli.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1613580697335-XWT4LDPINLYDIRJUNZN9/HS-Darya.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1611720002360-EYJPBMYMDUSAGVIFGJ1I/HS-JIMGODSEY.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1611720036616-M2OAYMCFNL7CJP6S4GQ1/HS-RobGrossman.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/4c92c2cd-3d1c-45b7-b6f7-cc8c15479dc8/Jerry+Lee+Headshot.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/8a0c2912-95fb-4872-887c-0d40445d581d/Traci+Pawlowski+Headshot.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/735fdeab-f90e-4cf8-9a70-ce750410a7f3/Elizabeth+Mansfield+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b5dba553-7bd2-4733-a49a-f3f3f9091e23/Screenshot+2025-11-14+at+8.31.28%E2%80%AFAM.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d4a953b5-d0fe-436f-9cc2-dddf00d1a0d1/John+Simmons+headshot.jpeg https://www.bloodpac.org/our-community daily 0.75 2026-03-19 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/579491ae-1c6d-49f2-a9e9-81361380d1bf/stella.png https://www.bloodpac.org/data-commons daily 0.75 2025-01-07 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/fe66a52c-1024-427c-92e9-8228ec730e54/DC-Video-Thumb.png BLOODPAC Data Commons - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.bloodpac.org/annual-and-financials daily 0.75 2025-12-03 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/6f5ba350-6c0c-4db6-88e8-193fcb3597bf/2024+Financials.png https://www.bloodpac.org/data-elements daily 0.75 2024-11-13 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1610132725412-76NZCZO0AU32239BEVA9/MTDE_paper_table.png Data Elements https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1610132824972-864WCUGXYGM3G3IOF61E/MTDE_workflow_table.png Data Elements https://www.bloodpac.org/data-submission-faqs daily 0.75 2023-04-18 https://www.bloodpac.org/bloodpac-governance daily 0.75 2024-11-13 https://www.bloodpac.org/collaborative-studies daily 0.75 2024-11-13 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1611710752943-DB6AYI7U88HCOHTK9VOA/iStock-1207212211.jpg Collaborative Studies - “BLOODPAC demonstrates the value of establishing open lines of collaboration among multiple stakeholders. This type of broad engagement allows for a better understanding of clinical, scientific and regulatory questions related to liquid biopsy that will ultimately drive the field forward and better serve the needs of patients” — Julia Beaver, Director, Division of Oncology 1, FDA https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1611711009973-A7AC25K4091CLMZK73NP/1200px-Breast_Cancer_Research_Foundation_logo.svg.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1614962298357-MTNZG2S167JWSL832QER/PCF.jpg https://www.bloodpac.org/frameworks-standards daily 0.75 2024-12-11 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1613573642144-8YBXDCEKFKMDCJOZO5NQ/frameworks-1.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1614962069628-H40AFAKMCIR3CYHA1KM8/MTDE.png https://www.bloodpac.org/reimbursement-and-policy daily 0.75 2024-12-12 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d69de296-13be-4fb7-9927-8c7a1208caac/Payer+WP+Website+Img+%281%29.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/6a7a27ad-5e2b-46b9-b17c-e6f84d54763e/memedu.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/10d1f476-ed45-4f1f-a1d4-bf227d1d5ac5/advocacy.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/ed1c2dfa-75eb-4b61-8cbc-0c18b0d2cfb6/payerengagment.png https://www.bloodpac.org/bp-publications daily 0.75 2023-02-20 https://www.bloodpac.org/white-house-cancer-moonshot daily 0.75 2022-08-27 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1614773017050-KZOQSQK38PTU1398642Y/WH2016.jpg White House Cancer Moonshot https://www.bloodpac.org/public-comments daily 0.75 2022-08-27 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d289d9a0-6cc6-4073-a190-d0a93bdee1bb/Docket+No.+FDA-2025-N-4622+Public+Comment+Thumbnail.png Public Comments January 23, 2026: Reclassification of Nucleic Acid-Based Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/f84ee326-4fd3-406d-a9e1-398b5b76d474/Public+Comment+Thumb+-+Letter+to+the+Editor.png Public Comments January 2025: Letter to the Editor about Huber et. al. https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/959c891a-a876-4708-adb8-ac9bfc3c6ac1/Public+Comment+Thumb.png Public Comments September 3rd, 2024: Blood-based Tests for Multiple Cancer Screening https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/813ff1c7-f0f0-42f9-b839-2a34b46a2a1d/Copy+of+Website++Public+Comment+Thumb+%283%29.png Public Comments December 20th, 2023: Docket No. FDA-2023-N-4720 Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3398430f-b718-4195-80a6-295c2bef5dc1/Copy+of+Website++Public+Comment+Thumb+%282%29.png Public Comments December 4th, 2023: Docket No. FDA-2023-N-2177 Medical Devices; Laboratory Developed Tests https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/8ac579b3-e7cf-41bb-9fa2-3e04bb09eb2a/Copy+of+Website++Public+Comment+Thumb+%281%29.png Public Comments October 27th, 2023: 2024 CLFS Preliminary Determinations https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/a4e9dc30-c9ae-4052-8064-ae1fc711f853/Copy+of+Website++Public+Comment+Thumb.png Public Comments September 8th, 2023: Genetic Testing for Oncology: DL39367 (First Coast) and DL39365 (Novitas) https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/41cbc6a4-09dc-459c-9ab2-e14461e612f8/Website++Public+Comment+2023+CLFS+Preliminary+Determinations.png Public Comments October 24, 2022: 2023 CLFS Preliminary Determinations https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/6c778196-424e-4f8d-8f5a-4dc97ff197f4/Public+Comment+Medicare+Physician+Fee+Schedule+Proposed+Rule+92022.png Public Comments September 1, 2022: Calendar Year (CY) 2023 Medicare Physician Fee Schedule Proposed Rule https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/5ff12be9-775f-4976-b539-fcde3664626e/Public+Comment+DL39367+_+DL39365.png Public Comments July 22, 2022: Genetic Testing for Oncology – DL39367 (First Coast) and DL39365 (Novitas) Submitted electronically https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/786cbf1b-dc87-4aea-9667-2737c4e0a09a/Public+Comment+DL37810+_+DA56867.png Public Comments November 11 2021: Public Comments for Proposed Local Coverage Determination, “Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms (DL37810)” and Draft Article “Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms (DA56867)” https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/be81a7e1-082c-4ee3-af65-9d92b1a14cdf/MCIT_10.14.21.png Public Comments Oct. 14, 2021: Proposed Rule to Repeal the Medicare Coverage of Innovative Technology (MCIT) implementation (CMS–3372–P2) https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/bc5ebead-20cd-492d-9904-6bf5bf07c9cd/G0327.png Public Comments July 15, 2021: G0327 Colorectal cancer screening; blood-based biomarker https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/c2a6d561-dbf9-45e5-82b2-9ab4efe52bc9/Reasonable+and+Necessary_04.16.2021.png Public Comments Apr. 16, 2021: Medicare Program; Medicare Coverage of Innovative Technology (MCIT) and Definition of ‘‘Reasonable and Necessary’’; Delay of Effective Date; Public Comment Period (CMS–3372–IFC) https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/85434a38-5c07-43cb-a189-303d227b576d/ReasonableNecessaryCTA.png Public Comments Nov. 2, 2020: Medicare Coverage of Innovative Technology & Definition of “Reasonable & Necessary” https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/f3b814a8-4b17-456a-9d61-a123b64f6fe0/DL38290CTA.png Public Comments Nov. 20, 2019: Proposed Local Coverage Determination (LCD) - MolDX: Signatera™ and MinimalResidual Disease Testing for Colorectal Cancer (DL38290) https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3c7b2059-abc6-46bc-9ea1-e9083621bb94/DL38043CTA.png Public Comments June 19, 2019: MolDX Local Coverage Determination (DL38043) https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/dd520a78-a4e9-4de6-baf2-41442b6139af/CMS-167-PCTA.png Public Comments Sept. 10, 2017: CMS-1678-P — Hospital Outpatient Prospective Payment System, Proposed Rule – Potential Revisions to the Laboratory Date of Service Policy https://www.bloodpac.org/member-publications daily 0.75 2025-09-18 https://www.bloodpac.org/bloodpac-portal daily 0.75 2024-11-13 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618497259178-6XJGK9GR6YAVBQL5L519/20140301_Trade-151_012-2.jpg BLOODPAC Portal https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1608066266418-CHQC49XZZNQKNA7TGGP4/20140228_Trade-151_0046.jpg BLOODPAC Portal https://www.bloodpac.org/membership-request daily 0.75 2023-04-05 https://www.bloodpac.org/discovery-portal-submission daily 0.75 2022-02-19 https://www.bloodpac.org/old-home daily 0.75 2025-09-02 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/e0c4909c-8b6a-4889-aea5-ac95bf17ff15/takeblood1.png Old Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1f589899-962a-472e-9f74-3b3f0ef8a51d/payberbkgd2.png Old Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/378f98d2-73a5-4d7a-91e0-313bd92bb6e2/Untitled+design+%281%29.png Old Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1613245464761-PQUQLR4WDNZ4RLAC539H/slideer-bw2-1.jpg Old Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1613245465431-25LWMEKD2EEZ8T282UWX/slideer-bw2-2.jpg Old Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1613245464425-X2MIIKJTCS5C3KP0023B/slideer-bw2-3.jpg Old Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1613245464595-7AWF18YZRG03DAPHFXU4/slideer-bw2-4.jpg Old Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d48c345f-25ad-458c-a712-76b4195b8c1d/evidence.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b0680bd2-ce34-467c-8940-5e05153dbf9a/data.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/15ba8d59-b26a-4ba4-a7d9-cbd4d8dba2b5/stakeholder.png https://www.bloodpac.org/insights daily 0.75 2024-10-17 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/af74d10d-80ed-42c2-bc2d-cfd715e66d47/blog-dark.png https://www.bloodpac.org/backup-blog daily 0.75 2023-02-20 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2597ad59-add9-4a88-b144-93c176001438/lab+dark.png https://www.bloodpac.org/annual-2022 daily 0.75 2023-09-05 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/ca409ea9-d42d-4c9b-a057-9a91f03f29e4/00035-20191202-LAURENLEIMAN-HED.jpg https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1589847902870-ZOUR0EX0L2QSQNRC1SP2/image-asset.jpeg https://www.bloodpac.org/home daily 1.0 2025-12-05 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2131f86a-b8a1-4d3b-92c5-c6537fb3ca89/IMG_2955.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/ed100094-c031-4a1a-b2c8-5f6d5304cc4b/IMG_3311.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/791ed5e2-107c-4dd5-a294-a10f1238536d/IMG_3293.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/1cfedd56-773f-48fc-8ffd-fb49783e04cb/Day+2+Photo+at+2025+Q3.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/4253d1e0-df74-4509-9896-0ded76e351b9/IMG_3286.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/21ccee69-7164-4c7e-9d8f-a62d8a1e3e0b/Group+Photo+2024+Q3.JPG Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3817047b-b9c7-4563-ac4e-f0d839ff8c7b/Rob+and+Jerry.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/34ec73fe-4c00-4301-9f32-44492b34665e/Copy+of+DSC09818.JPG Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/e6004ee2-6569-4f8f-ae3c-c1191d7cc2ed/Lauren+%26+Adam.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/456aaff4-568f-4d21-bd19-df8341cd1416/Accessibility+at+2024+Q3.png Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/7a5a6028-3d5c-4d00-8f39-98616b9e07d1/IMG_2217.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/0a4d42f4-4273-4665-8047-9dce1b3534b8/IMG_6065.jpeg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/c55e589b-f648-46ac-afdf-a1f3fb2c67b5/ED%26S+Group+Photo+at+2025+Q3.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/0c12d454-24d4-417b-820c-90a70e207a6c/Jim%2C+Cheyenne%2C+Dorys+Photo+at+2025+Q3.jpg Home https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d48c345f-25ad-458c-a712-76b4195b8c1d/evidence.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b0680bd2-ce34-467c-8940-5e05153dbf9a/data.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/15ba8d59-b26a-4ba4-a7d9-cbd4d8dba2b5/stakeholder.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/5e6426ef-d3d2-474d-ac77-4a0fb178ee51/jendickey.png https://www.bloodpac.org/how-we-work daily 0.75 2026-03-19 https://www.bloodpac.org/lexicon-manual daily 0.75 2025-03-31 https://www.bloodpac.org/data-science-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/82cc0a39-854d-4cc8-985a-ea857e80104f/Danne+Elbers+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/ff2fc9aa-729e-400c-bf70-d726e7c74bd9/Karl+Bisselou+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/ef6f26f8-bc8c-4e82-91c4-79e2def270ce/Prithwish+Pal+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/4b2bfb65-d868-4fff-812f-62d72d58257f/Data+Science+Publication+Thumbnail+for+Website.png https://www.bloodpac.org/mrd-analytical-validation-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/477b175c-1f4f-42be-b59c-6965320a9273/Jimmy+Lin+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/97931a76-4dc6-4454-8d3c-54fe5e638c06/Mark+Sausen+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/96da2700-cc8d-4e73-9a08-62051f3fca3e/MRD+AV+2026+Deliverable.png https://www.bloodpac.org/brain-tumor-working-group-learn-more daily 0.75 2025-12-04 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/c63a3bae-04c2-4821-a1e4-b1def38f7ad9/Graeme+Woodworth+Headshot.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/512c3136-da3f-4a16-8742-fc2ef869c6ff/Stephen+Bagley+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/4e0a4616-a5ba-49ef-a1cb-048c6f2bde3a/Minimum+Technical+Data+Elements+Publication+Thumbnail+for+Website.png https://www.bloodpac.org/btmb-analytical-validation-working-group-learn-more daily 0.75 2025-12-04 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2deb3390-da30-4211-9f30-b1275bccb4f1/Mark+Sausen+Headshot.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/89003512-8a86-4526-bbca-8059cf00c868/Jonathan+Baden+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/8a3e9443-07e4-4428-9daa-601f37a2b8ef/bTMB+AV+Publication+Thumbnail+for+Website.png https://www.bloodpac.org/analytical-validation-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/f3597e2a-3a91-4e38-865f-87432a67c336/Angela+Silvestro+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/aeaf4f8a-6faf-4eac-97de-7c724f551e00/Jim+Godsey+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/4bff592e-f96c-4888-ba26-45b7180e99c1/Generic+Protocols+AV+WG+Thumbnail+for+Website.png https://www.bloodpac.org/ch-chip-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/400ced28-a603-4ed0-8f6c-f7197b7bb7ce/Duane+Hassane+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3b7df3bc-164e-4c05-baf4-1e33c519b4de/Robert+Tell+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/00cf315f-03dc-4b24-a712-4c35aefa711c/Lexicon+for+Clonal+Hematopoiesis+in+Liquid+Biopsy.png https://www.bloodpac.org/early-detection-and-screening-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/92c48d0d-569c-4750-b99a-d1f9325fb3ee/Christina+Clarke+Dur+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/e38ef9ef-047a-4e2b-9e06-ffe2f08a3803/Bree+Mitchell+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/c4482a95-da82-4ffd-8148-95ccb2731b49/ED%26S+2022+Publication+Thumbnail+for+Website.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/673aff74-5151-4f7d-b892-2382dec6920c/ED%26S+August+2025+Publication+Thumbnail+for+Website.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2287d166-b807-411c-b26b-819fb4346998/ED%26S+2025+Deliverable.png https://www.bloodpac.org/jfdi-working-group-learn-more daily 0.75 2025-12-04 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/39651454-6bfd-4dcd-88b6-d90f80753e5e/Adam+Corner+Headshot.JPG https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/8886cabf-c067-40e9-bd01-c65153075d14/Jennifer+LoCoco+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3cd7506f-59e3-425d-beae-e9dbcd37e441/JFDI+2023+Manuscript.png https://www.bloodpac.org/mrd-strategic-steering-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/9c8d8b1a-e92c-4401-9a6d-31b0afe07a8d/Angela+Silvestro+Headshot.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/aeaf4f8a-6faf-4eac-97de-7c724f551e00/Jim+Godsey+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/867999ae-1298-4330-a9c3-f46f2533adae/MRD+Strategic+Steering+Manuscript+2025.png https://www.bloodpac.org/mrd-clinical-validation-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/a105a21c-f000-4230-a633-ed867066e896/Carol+Pena+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/ebc6f525-db9a-4c5c-a1cb-c6a51c486be2/Dan+Norton+Headshot.jpeg https://www.bloodpac.org/multi-omics-working-group-learn-more daily 0.75 2025-12-04 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3e7ee876-e1c0-4ab5-8503-a8e9463e8e98/Asaf+Zviran+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/8663b10e-fb9c-4068-84a5-962689d10ae3/Rebecca+Leary+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/5705c6db-c1c5-4ed2-906f-eb164e5240af/Wendy+Winckler+Headshot.jpeg https://www.bloodpac.org/recommended-data-elements-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b6fc8ba2-9bb0-47f2-bea9-75abddfac719/Jake+Vinson+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/490a374a-3215-4420-ae74-64894d6107da/Lauren+Saunders+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d7dba6ee-f37e-4964-8ecf-385783cb7195/RDE+2024+Deliverable.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3b6a6ced-7428-4355-b594-d211239db9a2/RDE+2025+Deliverable.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/5ff196a0-1645-4b4f-ace8-dd98aac5403d/RDE+2020+Deliverable.png https://www.bloodpac.org/accessibility-working-group-learn-more daily 0.75 2025-12-04 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b6e91a6f-74b5-471a-9e55-b668fe17bb40/Phillip+Febbo+Headshot.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d3bece51-740d-4ac0-96b2-421803611cfc/Robert+Dumanois+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/def29baa-f184-48ae-b28d-b648a373448e/Accessibility+2024+Deliverable.png https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/00117d45-0349-487d-8b35-3a43ee891318/Accessibility+2024+Deliverable.png https://www.bloodpac.org/blood-collection-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3381cd65-4310-405a-a7ca-869a99916637/Jennifer+Dickey+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/9f4ceacd-edf5-4a4e-9812-ba90e3727558/Kelli+Bramlett+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/ffbde4b6-599d-4d0a-b746-eb640c27974e/Blood+Collection+2024+Deliverable.png https://www.bloodpac.org/clinician-education-and-access-working-group-learn-more daily 0.75 2025-12-04 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b6e91a6f-74b5-471a-9e55-b668fe17bb40/Phillip+Febbo+Headshot.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d3bece51-740d-4ac0-96b2-421803611cfc/Robert+Dumanois+Headshot.jpeg https://www.bloodpac.org/bloodpac-portal-1 daily 0.75 2025-11-25 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618497259178-6XJGK9GR6YAVBQL5L519/20140301_Trade-151_012-2.jpg (COPY) BLOODPAC Portal https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1608066266418-CHQC49XZZNQKNA7TGGP4/20140228_Trade-151_0046.jpg (COPY) BLOODPAC Portal https://www.bloodpac.org/global-regulatory-working-group-learn-more daily 0.75 2026-03-16 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/b11b9e90-51aa-476e-983a-ae05aa1551ea/Elaine+Katrivanos+Headshot.jpg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/3381cd65-4310-405a-a7ca-869a99916637/Jennifer+Dickey+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/742d07f5-41d6-49c3-af7c-8828f7812fc1/Global+Regulatory+2025+Deliverable.png https://www.bloodpac.org/reimbursement-working-group-learn-more daily 0.75 2025-12-04 https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/d3bece51-740d-4ac0-96b2-421803611cfc/Robert+Dumanois+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/924ce79b-3c64-4f0c-9050-5bd36517b40c/Suzanne+Belinson+Headshot.jpeg https://images.squarespace-cdn.com/content/v1/5f9346ec7a77064e62dee0ad/2c6b1dd4-782a-4140-87fe-df0b3815cb6f/Reimbursement+2024+Deliverable.png